Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Silexion Therapeutics stock falls after warrant exercise deal | 2 | Investing.com | ||
Fr | Silexion-Aktie stürzt nach Vereinbarung zur Ausübung von Optionsscheinen ab/n | 5 | Investing.com Deutsch | ||
Fr | Silexion Therapeutics Corp: Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds | 1 | GlobeNewswire (USA) | ||
Do | Why Is Silexion Therapeutics Stock Trading Higher On Thursday? | 1 | Benzinga.com | ||
Do | Silexion reports 97% cancer cell inhibition with KRAS therapy | 3 | Investing.com | ||
SILEXION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
Do | Silexion Therapeutics Corp: Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation | 111 | GlobeNewswire (Europe) | Grand Cayman, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi)... ► Artikel lesen | |
29.07. | Silexion Therapeutics setzt Aktienzusammenlegung im Verhältnis 1:15 um | 2 | Investing.com Deutsch | ||
29.07. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
17.07. | Silexion Announces 1-for-15 Reverse Share Split To Regain Nasdaq Compliance | 1 | RTTNews | ||
16.07. | Silexion kündigt Reverse Split im Verhältnis 1:15 zur Sicherung des NASDAQ-Listings an | 1 | Investing.com Deutsch | ||
16.07. | Silexion announces 1-for-15 reverse share split effective July 29 | 1 | Investing.com | ||
16.07. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
16.07. | Silexion Therapeutics Corp: Silexion Therapeutics Announces 1-for-15 Reverse Share Split | 160 | GlobeNewswire (Europe) | Grand Cayman, Cayman Islands, July 16, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
14.07. | Silexion Therapeutics: Aktionäre genehmigen Verwaltungsratswahl, Aktienzusammenlegung und Änderungen am Eigenkapital-Plan | 1 | Investing.com Deutsch | ||
09.07. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines | 274 | GlobeNewswire (Europe) | Grand Cayman, Cayman Islands, July 09, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
08.07. | Silexion Therapeutics sichert sich Verbleib an der NASDAQ unter Auflagen | 1 | Investing.com Deutsch | ||
08.07. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
29.05. | Silexion Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
29.05. | Silexion reports breakthrough in KRAS-driven cancer therapy | 3 | Investing.com | ||
29.05. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers | 238 | GlobeNewswire (Europe) | GRAND CAYMAN, Cayman Islands, May 29, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 94,30 | -1,77 % | Ihre wichtigsten Termine: Tyson Foods, Biontech, Adtran, Loews, VDMA und Stabilus stehen heute im Fokus! | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Luxemburg:... ► Artikel lesen | |
CUREVAC | 4,680 | -0,68 % | CureVac Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
AMGEN | 244,50 | -5,80 % | Amgen hebt Prognose nach überraschend gut verlaufenem Quartal an | THOUSAND OAKS (dpa-AFX) - Der US-Biotechkonzern Amgen blickt nach einem überraschend gut gelaufenen Quartal optimistischer auf 2025. Der Umsatz dürfte bei 35 bis 36 Milliarden US-Dollar liegen, teilte... ► Artikel lesen | |
NOVAVAX | 6,589 | +13,04 % | Novavax, Inc.: Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights | Total revenue of $239 million in the second quarter of 2025
Received FDA BLA approval for Nuvaxovid, the only recombinant protein-based, non-mRNA COVID-19 vaccine... ► Artikel lesen | |
BIOGEN | 111,15 | -3,26 % | Biogen-Aktie: Kurs mit wenig Bewegung (114,5994 €) | Im US-amerikanischen Wertpapierhandel ist das Wertpapier von Biogen derzeit unauffällig. Die Aktie kostete zuletzt 132,69 US-Dollar. Ein geringes Kursplus von 0,38 Prozent zeigt die Kurstafel für die... ► Artikel lesen | |
MAINZ BIOMED | 1,510 | 0,00 % | Mainz BioMed NV: Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants | BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
VIKING THERAPEUTICS | 27,185 | -7,52 % | Is Viking Therapeutics the Next Big Biotech Bet? | ||
INTELLIA THERAPEUTICS | 9,642 | -3,50 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
GENMAB | 185,00 | -3,37 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2025 | Company Announcement Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 7,380 | +2,07 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
TEMPUS AI | 47,600 | -4,80 % | If You'd Invested $1,000 in Tempus AI Stock (TEM) 1 Year Ago, Here's How Much You'd Have Today | ||
SAREPTA THERAPEUTICS | 13,970 | -3,42 % | Sarepta-Aktie: +87,8% über Nacht - Sharedeals-Leser feiern | Bei Sarepta Therapeutics explodiert der Kurs innerhalb von wenigen Stunden nach einem exklusiven Tipp auf sharedeals.de. Was steckt hinter dem Coup - und wie findest Du den nächsten Depot-Turbo? Gideon... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 0,909 | -21,91 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx in Acute Myocarditis | Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx over placebo.Reduction in ECV was associated with improvements... ► Artikel lesen | |
EXELIXIS | 32,290 | -0,22 % | Exelixis, Inc.: Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors | - Approval is based on the phase 3 CABINET pivotal trial, in which CABOMETYX demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,218 | -0,38 % | Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models |